<DOC>
	<DOCNO>NCT00517049</DOCNO>
	<brief_summary>This Phase II , single-arm , open-label , multicenter trial design evaluate safety , efficacy , pharmacokinetics PRO95780 combine rituximab patient follicular , CD20-positive B-cell NHL progress follow previous rituximab therapy .</brief_summary>
	<brief_title>A Study PRO95780 Combination With Rituximab Patients With Non-Hodgkin 's Lymphoma That Has Progressed Following Previous Rituximab Therapy ( APM4083g )</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Signed Informed Consent Form Age â‰¥ 18 year Diagnosis follicular , CD20positive Bcell NHL Progression disease objective response stable disease last &gt; 6 month follow completion recent rituximabcontaining regimen Measurable disease Life expectancy &gt; 3 month Grade 3b follicular lymphoma ( accord WHO classification ) histologic transformation follicular lymphoma aggressive lymphoma Prior radiotherapy lesion ( ) use assess response unless lesion ( ) show clear evidence lymphoma progression baseline Radiotherapy peripheral lesion within 14 day prior Cycle 1 , Day 1 radiotherapy thoracic , abdominal , pelvic field within 28 day prior Cycle 1 , Day 1 Concurrent systemic corticosteroid therapy Other invasive malignancy within 3 year prior first study drug administration except adequately treat basal squamous cell skin cancer , situ carcinoma cervix , situ breast cancer , situ prostate cancer , limitedstage bladder cancer , cancer patient diseasefree least 3 year . History evidence physical examination central nervous system ( CNS ) disease Prior treatment agonistic DR4 DR5 antibody Apo2L/TRAIL</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>NHL</keyword>
	<keyword>Rituxan</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>CD20-positive</keyword>
	<keyword>B-Cell</keyword>
	<keyword>APM4083g</keyword>
</DOC>